Table 5.
Subgroup comparisons and cox-regression predictors of outcomes for a subset composed of patients with chronic hepatitis C virus and propensity score matched patients without hepatitis C virus, n (%)
|
Propensity score matched (n = 72)
|
|||||||
|
Comparison between groups
|
Cox-regression analysis
|
||||||
|
Univariate
|
Multivariate
|
||||||
|
NO HCV (n = 48)
|
HCV with viral load (n = 24)
|
P
value
|
Exp (B)
|
Sig.
|
Exp (B)
|
Sig.
|
|
| Age (yr) | 64.4 ± 15.1 | 64.4 ± 9.8 | 0.995 | 1.021 | 0.293 | - | - |
| Gender (female) | 28 (58) | 17 (71) | 0.302 | 0.481 | 0.088 | - | - |
| Body mass index (kg/m2) | 27.9 ± 6.8 | 26.0 ± 6.2 | 0.252 | 1.014 | 0.625 | - | - |
| Hypertension | 33 (69) | 16 (67) | 0.858 | 3.03 | 0.014 | 2.55 | 0.035 |
| Diabetes mellitus | 17 (35) | 7 (29) | 0.596 | 1.05 | 0.902 | - | - |
| Human immune-deficiency virus | 17 (35) | 9 (38) | 0.862 | 1.79 | 0.185 | - | - |
| Asthma | 9 (19) | 4 (17) | 0.828 | 1.81 | 0.251 | - | - |
| Chronic obstructive pulmonary disease | 9 (19) | 5 (21) | 0.833 | 1.386 | 0.483 | - | - |
| Hepatitis B infection | 1 (0.2) | 0 (0) | 0.476 | 1.04 | 0.976 | - | - |
| HCV | 0 (0) | 24 (100) | - | 3.47 | 0.007 | 3.2 | 0.014 |
| Congestive heart failure | 10 (21) | 5 (21) | 1.000 | 1.41 | 0.448 | - | - |
| Coronary artery disease | 6 (13) | 2 (8) | 0.596 | 1.12 | 0.845 | - | - |
| End stage renal disease | 2 (0.4) | 1 (4) | 1.000 | 1.65 | 0.628 | - | - |
| Chronic kidney disease | 5 (10) | 6 (25) | 0.105 | 1.1 | 0.875 | - | - |
| Hemoglobin | 12.5 ± 2.1 | 11.7 ± 2.6 | 0.166 | 0.921 | 0.424 | - | - |
| Total white count | 7.8 ± 3.5 | 12 ± 17.9 | 0.122 | 1.006 | 0.618 | - | - |
| Platelets | 234.4 ± 100.3 | 185 ± 86.2 | 0.051 | 1.000 | 0.978 | - | - |
| Neutrophilic count | 6.27 ± 3.4 | 6.24 ± 4.3 | 0.981 | 1.11 | 0.056 | - | - |
| Lymphocyte count | 0.99 ± 0.5 | 4.62 ± 17.0 | 0.145 | 1.002 | 0.897 | - | - |
| D-dimer | 6883 ± 28017 | 1154 ± 1807 | 0.333 | 1.000 | 0.054 | - | - |
| Lactate dehydrogenase | 523 ± 419 | 649 ± 484 | 0.273 | 1.000 | 0.898 | - | - |
| High sensitivity C-reactive protein | 129 ± 90 | 113 ± 89 | 0.518 | 0.999 | 0.751 | - | - |
| Ferritin | 1053 ± 1267 | 1373 ± 2775 | 0.533 | 1.000 | 0.661 | - | - |
| Prothrombin time (s) | 13.6 ± 2.3 | 13.5 ± 2.5 | 0.820 | 1.05 | 0.636 | - | - |
| Activated partial thromboplastin time (s) | 31.4 ± 5.4 | 32.9 ± 7.28 | 0.365 | 0.935 | 0.138 | - | - |
| Creatinine | 2.01 ± 2.4 | 3.2 ± 4. | 0.132 | 1.06 | 0.315 | - | - |
| Alanine transaminase | 40.8 ± 37.5 | 62.1 ± 169.8 | 0.448 | 0.998 | 0.427 | - | - |
| Aspartate transaminase | 59.8 ± 43.5 | 169.8 ± 518.6 | 0.185 | 0.999 | 0.433 | - | - |
| Alkaline phosphatase | 82.3 ± 40.7 | 114.5 ± 165.7 | 0.246 | 0.996 | 0.376 | - | - |
| Total bilirubin | 0.54 ± 0.4 | 0.93 ± 1.1 | 0.05 | 1.236 | 0.336 | - | - |
| Combined bilirubin | 0.26 ± 0.28 | 0.58 ± 0.9 | 0.05 | 1.223 | 0.428 | - | - |
| Total protein | 6.91 ± 0.72 | 7.0 ± 0.95 | 0.618 | 0.813 | 0.380 | - | - |
| Albumin | 3.6 ± 0.51 | 3.3 ± 0.52 | 0.073 | 0.509 | 0.079 | - | - |
| Procalcitonin | 3.1 ± 8.8 | 4.6 ± 11.7 | 0.695 | 0.984 | 0.538 | - | - |
| Hydroxychloroquine | 33 (69) | 18 (75) | 0.582 | - | - | - | - |
| Azithromycin | 35 (73) | 13 (54) | 0.112 | - | - | - | - |
| Tocilizumab | 4 (8) | 0 (0) | 0.146 | - | - | - | - |
| Mechanical ventilation | 4 (8) | 15 (63) | < 0.001 | - | - | - | - |
| Death | 7 (15) | 15 (63) | < 0.001 | - | - | - | - |
HCV: Hepatitis C virus.